Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
The aim of this study was to determine the efficacy of two hepatitis C virus (HCV) real-time PCR assays, the COBAS AmpliPrep/COBAS TaqMan HCV test (CAP/CTM) and the Abbott RealTime HCV test (ART), for predicting the clinical outcomes of patients infected with HCV who received telaprevir (TVR)-based...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5261727?pdf=render |
| _version_ | 1818144940723535872 |
|---|---|
| author | Takako Inoue Su Su Hmwe Noritomo Shimada Keizo Kato Tatsuya Ide Takuji Torimura Takashi Kumada Hidenori Toyoda Akihito Tsubota Koichi Takaguchi Takaji Wakita Yasuhito Tanaka |
| author_facet | Takako Inoue Su Su Hmwe Noritomo Shimada Keizo Kato Tatsuya Ide Takuji Torimura Takashi Kumada Hidenori Toyoda Akihito Tsubota Koichi Takaguchi Takaji Wakita Yasuhito Tanaka |
| author_sort | Takako Inoue |
| collection | DOAJ |
| description | The aim of this study was to determine the efficacy of two hepatitis C virus (HCV) real-time PCR assays, the COBAS AmpliPrep/COBAS TaqMan HCV test (CAP/CTM) and the Abbott RealTime HCV test (ART), for predicting the clinical outcomes of patients infected with HCV who received telaprevir (TVR)-based triple therapy or daclatasvir/asunaprevir (DCV/ASV) dual therapy. The rapid virological response rates in patients receiving TVR-based triple therapy were 92% (23/25) and 40% (10/25) for CAP/CTM and ART, respectively. The false omission rate (FOR) of ART was 93.3% (14/15), indicating that CAP/CTM could accurately predict clinical outcome in the early phase. In an independent examination of 20 patients receiving TVR-based triple therapy who developed viral breakthrough or relapse, the times to HCV disappearance by ART were longer than by CAP/CTM, whereas the times to HCV reappearance were similar. In an independent experiment of WHO standard HCV RNA serially diluted in serum containing TVR, the analytical sensitivities of CAP/CTM and ART were similar. However, cell cultures transfected with HCV and grown in medium containing TVR demonstrated that ART detected HCV RNA for a longer time than CAP/CTM. Similar results were found for 42 patients receiving DCV/ASV dual therapy. The FOR of ART was 73.3% (11/15) at week 8 after initiation of therapy, indicating that ART at week 8 could not accurately predict the clinical outcome. In conclusion, although CAP/CTM and ART detected HCV RNA with comparable analytical sensitivity, CAP/CTM might be preferable for predicting the clinical outcomes of patients receiving protease inhibitor-based therapy. |
| first_indexed | 2024-12-11T11:55:33Z |
| format | Article |
| id | doaj.art-a046889e59a0456097575db7edce7678 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T11:55:33Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a046889e59a0456097575db7edce76782022-12-22T01:08:13ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01121e017066710.1371/journal.pone.0170667Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.Takako InoueSu Su HmweNoritomo ShimadaKeizo KatoTatsuya IdeTakuji TorimuraTakashi KumadaHidenori ToyodaAkihito TsubotaKoichi TakaguchiTakaji WakitaYasuhito TanakaThe aim of this study was to determine the efficacy of two hepatitis C virus (HCV) real-time PCR assays, the COBAS AmpliPrep/COBAS TaqMan HCV test (CAP/CTM) and the Abbott RealTime HCV test (ART), for predicting the clinical outcomes of patients infected with HCV who received telaprevir (TVR)-based triple therapy or daclatasvir/asunaprevir (DCV/ASV) dual therapy. The rapid virological response rates in patients receiving TVR-based triple therapy were 92% (23/25) and 40% (10/25) for CAP/CTM and ART, respectively. The false omission rate (FOR) of ART was 93.3% (14/15), indicating that CAP/CTM could accurately predict clinical outcome in the early phase. In an independent examination of 20 patients receiving TVR-based triple therapy who developed viral breakthrough or relapse, the times to HCV disappearance by ART were longer than by CAP/CTM, whereas the times to HCV reappearance were similar. In an independent experiment of WHO standard HCV RNA serially diluted in serum containing TVR, the analytical sensitivities of CAP/CTM and ART were similar. However, cell cultures transfected with HCV and grown in medium containing TVR demonstrated that ART detected HCV RNA for a longer time than CAP/CTM. Similar results were found for 42 patients receiving DCV/ASV dual therapy. The FOR of ART was 73.3% (11/15) at week 8 after initiation of therapy, indicating that ART at week 8 could not accurately predict the clinical outcome. In conclusion, although CAP/CTM and ART detected HCV RNA with comparable analytical sensitivity, CAP/CTM might be preferable for predicting the clinical outcomes of patients receiving protease inhibitor-based therapy.http://europepmc.org/articles/PMC5261727?pdf=render |
| spellingShingle | Takako Inoue Su Su Hmwe Noritomo Shimada Keizo Kato Tatsuya Ide Takuji Torimura Takashi Kumada Hidenori Toyoda Akihito Tsubota Koichi Takaguchi Takaji Wakita Yasuhito Tanaka Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. PLoS ONE |
| title | Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. |
| title_full | Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. |
| title_fullStr | Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. |
| title_full_unstemmed | Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. |
| title_short | Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. |
| title_sort | clinical significance of two real time pcr assays for chronic hepatitis c patients receiving protease inhibitor based therapy |
| url | http://europepmc.org/articles/PMC5261727?pdf=render |
| work_keys_str_mv | AT takakoinoue clinicalsignificanceoftworealtimepcrassaysforchronichepatitiscpatientsreceivingproteaseinhibitorbasedtherapy AT susuhmwe clinicalsignificanceoftworealtimepcrassaysforchronichepatitiscpatientsreceivingproteaseinhibitorbasedtherapy AT noritomoshimada clinicalsignificanceoftworealtimepcrassaysforchronichepatitiscpatientsreceivingproteaseinhibitorbasedtherapy AT keizokato clinicalsignificanceoftworealtimepcrassaysforchronichepatitiscpatientsreceivingproteaseinhibitorbasedtherapy AT tatsuyaide clinicalsignificanceoftworealtimepcrassaysforchronichepatitiscpatientsreceivingproteaseinhibitorbasedtherapy AT takujitorimura clinicalsignificanceoftworealtimepcrassaysforchronichepatitiscpatientsreceivingproteaseinhibitorbasedtherapy AT takashikumada clinicalsignificanceoftworealtimepcrassaysforchronichepatitiscpatientsreceivingproteaseinhibitorbasedtherapy AT hidenoritoyoda clinicalsignificanceoftworealtimepcrassaysforchronichepatitiscpatientsreceivingproteaseinhibitorbasedtherapy AT akihitotsubota clinicalsignificanceoftworealtimepcrassaysforchronichepatitiscpatientsreceivingproteaseinhibitorbasedtherapy AT koichitakaguchi clinicalsignificanceoftworealtimepcrassaysforchronichepatitiscpatientsreceivingproteaseinhibitorbasedtherapy AT takajiwakita clinicalsignificanceoftworealtimepcrassaysforchronichepatitiscpatientsreceivingproteaseinhibitorbasedtherapy AT yasuhitotanaka clinicalsignificanceoftworealtimepcrassaysforchronichepatitiscpatientsreceivingproteaseinhibitorbasedtherapy |